Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - tipiracil hydrochloride, quantity: 7.065 mg; trifluridine, quantity: 15 mg - tablet, film coated - excipient ingredients: carnauba wax; pregelatinised maize starch; lactose monohydrate; iron oxide yellow; titanium dioxide; macrogol 8000; indigo carmine aluminium lake; hypromellose; stearic acid; iron oxide red; shellac; purified talc; magnesium stearate - colorectal cancer lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.,gastric cancer lonsurf is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - trifluridine, quantity: 20 mg; tipiracil hydrochloride, quantity: 9.42 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 8000; titanium dioxide; hypromellose; indigo carmine aluminium lake; iron oxide yellow; carnauba wax; magnesium stearate; lactose monohydrate; iron oxide red; shellac; pregelatinised maize starch - colorectal cancer lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.,gastric cancer lonsurf is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - tipiracil hydrochloride, quantity: 7.065 mg; trifluridine, quantity: 15 mg - tablet, film coated - excipient ingredients: macrogol 8000; lactose monohydrate; indigo carmine aluminium lake; pregelatinised maize starch; shellac; magnesium stearate; titanium dioxide; iron oxide red; stearic acid; iron oxide yellow; hypromellose; carnauba wax; purified water - colorectal cancer orcantas is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.,gastric cancer orcantas is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - trifluridine; tipiracil hydrochloride -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - trifluridine; tipiracil hydrochloride -

European Union - English - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hydrochloride - colorectal neoplasms - antineoplastic agents - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents.lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - trifluridine, quantity: 20 mg; tipiracil hydrochloride, quantity: 9.42 mg - tablet, film coated - excipient ingredients: lactose monohydrate; macrogol 8000; stearic acid; pregelatinised maize starch; carnauba wax; titanium dioxide; iron oxide red; purified talc; hypromellose; shellac; indigo carmine aluminium lake; iron oxide yellow; magnesium stearate - colorectal cancer orcantas is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.,gastric cancer orcantas is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy.

United States - English - NLM (National Library of Medicine)

hi-tech pharmacal co., inc. - trifluridine (unii: rmw9v5rw38) (trifluridine - unii:rmw9v5rw38) - trifluridine 10 mg in 1 ml - trifluridine ophthalmic solution, 1% (trifluridine ophthalmic solution) is indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2. trifluridine ophthalmic solution, 1% is contraindicated for patients who develop hypersensitivity reactions or chemical intolerance to trifluridine.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

servier laboratories ltd - trifluridine; tipiracil hydrochloride - tablet - 15mg ; 6.14mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

servier laboratories ltd - tipiracil hydrochloride; trifluridine - tablet - 8.19mg ; 20mg